Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.46 |
| ▸ | NGFR | P08138 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838149 | 0.80 | KDM4E (0.56) | KDM4EHSD17B10ALDH1A1LMNASMAD3 | |
| SCHEMBL2567378 | 0.79 | ALOX15 (0.47) | KDM4EALDH1A1GRIN1GRIN2DGRIN2A | |
| SCHEMBL7471060 | 0.79 | KDM4E (0.52) | KDM4EHSD17B10ALDH1A1LMNAHPGD | |
| SCHEMBL27482998 | 0.77 | KDM4E (0.53) | KDM4EHSD17B10ALDH1A1LMNASMAD3 | |
| SCHEMBL14916137 | 0.76 | HRH4 (0.66) | — | |
| SCHEMBL14916494 | 0.76 | ERN1 (0.55) | ERN1 | |
| SCHEMBL30406065 | 0.75 | NPC1 (0.44) | KDM4EHSD17B10ALDH1A1LMNAHPGD | |
| SCHEMBL22840481 | 0.75 | KDM4E (0.43) | KDM4EHSD17B10ALDH1A1HPGDERN1 | |
| SCHEMBL21180073 | 0.74 | ERN1 (0.44) | ERN1 | |
| SCHEMBL2565847 | 0.74 | HTR2C (0.55) | KDM4EHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-9867803-B2 | IRE-1α inhibitors | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-11-16 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693992-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | KDM4E 2950/4885HSD17B10 2046/4885ALDH1A1 2024/4885 |
| US-20170326104-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | KDM4E 2950/4885HSD17B10 2046/4885ALDH1A1 2024/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | KDM4E 2619/4885HSD17B10 2082/4885ALDH1A1 1815/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | KDM4E 2950/4885HSD17B10 2046/4885ALDH1A1 2024/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | KDM4E 2619/4885HSD17B10 2082/4885ALDH1A1 1815/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | KDM4E 2975/4885HSD17B10 2092/4885ALDH1A1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.